Anti‐angiogenic efficacy of aflibercept and bevacizumab in primary oral squamous cell carcinoma cells

Ganjibakhsh, Meysam; Monshizadeh, Roshanak; Nasimian, Ahmad; Aminishakib, Pouyan; Farzaneh, Parvaneh; Shiraji, Sahar Tavakoli; Gharajei, Ata; Rahrotaban, Sedigheh; Baghaei, Fereshteh; Gohari, Neda Sadat

doi:10.1111/jop.12717

Cited by 12 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aflibercept is a compound simulating VEGF receptor, capable of downregulating not only VEGF-A, but also VEGF-B and placental growth factor. Because of different characteristics of two anti-VEGF agents, aflibercept had higher binding affinity of VEGF than bevacizumab in cell-based bioassays 31 , 32 . Aflibercept displayed a more prolonged VEGF inhibition in comparison with bevacizumab on retinal pigment epithelium/choroid organ cultures 33 .…”

Section: Discussionmentioning

confidence: 99%

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

Wang

Huang

Chang

et al. 2018

Sci Rep

View full text Add to dashboard Cite

The authors performed a retrospective and comparative study to compare the efficacy of intravitreal aflibercept and bevacizumab for patients with myopic choroidal neovascularization (mCNV). The patients with treatment-naïve mCNV received 1 + PRN intravitreal bevacizumab from March 2008 to February 2013, while from March 2013 to July 2016 patients were treated by 1 + PRN intravitreal aflibercept, all with monthly follow-up for 12 months. Primary outcome measures included change in central foveal thickness (CFT) in 1 mm by spectral-domain optic coherence tomography, and best corrected visual acuity (BCVA) at month 12. Complications after injections were recorded. The intra-group changes in CFT and BCVA were compared with Wilcoxon signed rank test, the between-group difference compared with Wilcoxon rank sum test. Fisher’s exact test was used for categorical comparison between groups. Seventy-eight eyes of 78 patients were collected. There were 42 eyes in bevacizumab group, with mean age of 53.2 ± 5.4 years and 27 female patients of them. The mean BCVA significantly improved from baseline 0.56 ± 0.35 logMAR to 0.35 ± 0.35 logMAR at Month 12 after bevacizumab treatment (p < 0.001). The mean CFT significantly decreased from baseline 315.3 ± 25.6 μm to 253.7 ± 24.4 μm at Month 12 following intravitreal bevacizumab (p < 0.001). There were 36 eyes in aflibercept group, with mean age of 52.8 ± 6.8 years and 24 female patients of them. The mean BCVA significantly improved from baseline 0.61 ± 0.47 logMAR to 0.38 ± 0.41 logMAR at Month 12 after aflibercept treatment (p < 0.001). The mean CFT significantly decreased from baseline 328.2 ± 19.8 μm to 241.8 ± 27.2 μm at Month 12 following intravitreal aflibercept (p < 0.001). The baseline demographics, lens status, axial length, refractive errors, duration of symptoms, BCVA, and CFT did not differ significantly between groups (p > 0.05). There was no significant difference between bevacizumab and aflibercept groups in BCVA and CFT from Month 1 to Month 12 (p > 0.05). Injection number of aflibercept was 2.11 ± 0.41, less than that of bevacizumab (3.23 ± 0.38) during 12-month period (p = 0.01). There were no systemic thromboembolic event, elevated intraocular pressure, retinal detachment, or infectious endophthalmitis following injections in both groups. We concluded that both aflibercept and bevacizumab can effectively treat choroidal neovascularization in high myopes. Intravitreal aflibercept had similar efficacy but less treatment number than bevacizumab for mCNV during 12-month period.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

Wang

Huang

Chang

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Thus, different strategies to inhibit the VEGF/VEGFR signaling pathway have been developed [1]. Angiogenesis inhibition by targeting VEGF has shown to be an effective treatment of OSCC in in vivo animal models [70][71][72] and in vitro [73]. There are several anti-VEGF family agents, which include bevacizumab, sorafenib, vandetanib, among others [74], that have been tested for OSCC treatment.…”

Section: Therapy and Projectionsmentioning

confidence: 99%

Vascular Endothelial Growth Factor: A Translational View in Oral Non-Communicable Diseases

et al. 2021

View full text Add to dashboard Cite

Vascular endothelial growth factors (VEGFs) are vital regulators of angiogenesis that are expressed in response to soluble mediators, such as cytokines and growth factors. Their physiologic functions include blood vessel formation, regulation of vascular permeability, stem cell and monocyte/macrophage recruitment and maintenance of bone homeostasis and repair. In addition, angiogenesis plays a pivotal role in chronic pathologic conditions, such as tumorigenesis, inflammatory immune diseases and bone loss. According to their prevalence, morbidity and mortality, inflammatory diseases affecting periodontal tissues and oral cancer are relevant non-communicable diseases. Whereas oral squamous cell carcinoma (OSCC) is considered one of the most common cancers worldwide, destructive inflammatory periodontal diseases, on the other hand, are amongst the most prevalent chronic inflammatory conditions affecting humans and also represent the main cause of tooth loss in adults. In the recent years, while knowledge regarding the role of VEGF signaling in common oral diseases is expanding, new potential translational applications emerge. In the present narrative review we aim to explore the role of VEGF signaling in oral cancer and destructive periodontal inflammatory diseases, with emphasis in its translational applications as potential biomarkers and therapeutic targets.

show abstract

“…Bevacizumab injections decreased tumor growth in OSCC xenografts [ 95 ]. In a study comparing bevacizumab and aflibercept, the migration rate of cells was much lower when aflibercept was applied [ 87 ]. Sorafenib, used in combination with radiotherapy, suppressed NF-κB and associated proteins, which are involved in tumorigenesis and radioresistance [ 96 ].…”

Section: Targeted Gene Therapymentioning

confidence: 99%

“…Representative drugs currently available or under investigation for the treatment of OSCC[85][86][87]. Only cetuximab, pembrolizumab, and nivolumab have been approved by the FDA for application on HNSCC/OSCC treatment.…”

mentioning

confidence: 99%

The Application of Next-Generation Sequencing to Define Factors Related to Oral Cancer and Discover Novel Biomarkers

Kim

Lee

Park

2020

Life

View full text Add to dashboard Cite

Despite the introduction of next-generation sequencing in the realm of DNA sequencing technology, it is not often used in the investigation of oral squamous cell carcinoma (OSCC). Oral cancer is one of the most frequently occurring malignancies in some parts of the world and has a high mortality rate. Patients with this malignancy are likely to have a poor prognosis and may suffer from severe facial deformity or mastication problems even after successful treatment. Therefore, a thorough understanding of this malignancy is essential to prevent and treat it. This review sought to highlight the contributions of next-generation sequencing (NGS) in unveiling the genetic alterations and differential expressions of miRNAs involved in OSCC progression. By applying an appropriate eligibility criterion, we selected relevant studies for review. Frequently identified mutations in genes such as TP53, NOTCH1, and PIK3CA are discussed. The findings of existing miRNAs (e.g., miR-21) as well as novel discoveries pertaining to OSCC are also covered. Lastly, we briefly mention the latest findings in targeted gene therapy and the potential use of miRNAs as biomarkers. Our goal is to encourage researchers to further adopt NGS in their studies and give an overview of the latest findings of OSCC treatment.

show abstract

Anti‐angiogenic efficacy of aflibercept and bevacizumab in primary oral squamous cell carcinoma cells

Abstract: The anti-angiogenic-targeted drugs, especially Af, might be effective in treatment of patients with OSCC in combination with conventional surgical treatments.

Cited by 12 publications

References 25 publications

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

Vascular Endothelial Growth Factor: A Translational View in Oral Non-Communicable Diseases

The Application of Next-Generation Sequencing to Define Factors Related to Oral Cancer and Discover Novel Biomarkers

Contact Info

Product

Resources

About